Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for ... Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Show more
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and...
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness...
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific...
THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade...
THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA® (sotagliflozin...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.09 | -5.11363636364 | 1.76 | 1.765 | 1.59 | 2451194 | 1.66136068 | CS |
4 | -0.0599 | -3.46262789757 | 1.7299 | 2.03 | 1.59 | 2541459 | 1.77473207 | CS |
12 | -0.34 | -16.9154228856 | 2.01 | 2.04 | 1.48 | 2660342 | 1.73325886 | CS |
26 | 0.035 | 2.14067278287 | 1.635 | 3.73 | 1.24 | 3687784 | 2.15482123 | CS |
52 | -0.64 | -27.7056277056 | 2.31 | 3.73 | 0.92 | 2896515 | 1.87005666 | CS |
156 | -2.42 | -59.1687041565 | 4.09 | 6.3299 | 0.92 | 1610320 | 2.3182816 | CS |
260 | -4.7 | -73.7833594976 | 6.37 | 9.65 | 0.92 | 2001600 | 3.13826635 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.